Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Vertex Pharmaceuticals (NASDAQ ... “VRTX delivered its usual top-line beat offset by higher R&D and SG&A investments for advancements into late-stage/pivotal studies and recent launches, respectively, ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Vertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly shy of expectations, top-line revenue growth was a significant beat.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

After hours: February 14 at 6:18:06 PM EST Loading Chart for LINE ...

At close: 14 February at 5:16:41 pm GMT-5 ...

Keep up with the markets, earnings, and economy with high-quality news from 1,000s of journalists around the world.